Last reviewed · How we verify
NCT03361436
Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
Phase 1 trial testing Eribulin Mesylate in Liposarcoma in 15 participants. Participants enrolled and being followed up; not accepting new ones.
14 February 2023
Quick facts
| Lead sponsor | OHSU Knight Cancer Institute |
|---|---|
| Phase | Phase 1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 19 March 2018 |
| Primary completion | 14 February 2023 |
| Estimated completion | 14 April 2033 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Eribulin Mesylate — full drug profile →
- Intensity-Modulated Radiation Therapy
- Laboratory Biomarker Analysis — full drug profile →
- Quality-of-Life Assessment
- Questionnaire Administration
- Therapeutic Conventional Surgery
Conditions studied
- Liposarcoma — all drugs for Liposarcoma →
- Malignant Abdominal Neoplasm — all drugs for Malignant Abdominal Neoplasm →
- Malignant Retroperitoneal Neoplasm — all drugs for Malignant Retroperitoneal Neoplasm →
- Malignant Scrotal Neoplasm — all drugs for Malignant Scrotal Neoplasm →
Sponsor
OHSU Knight Cancer Institute
Who can join
12 and older, any sex, with Liposarcoma or Malignant Abdominal Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase Ib trials studies the side effects and best dose of eribulin mesylate when given together with radiation therapy in treating patients with retroperitoneal liposarcoma that can be removed by surgery. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Concurrent preoperative eribulin and radiation for resectable retroperitoneal liposarcoma: a phase 1B study
Davis L, Zhu L, Mayo SC, Latour E, et al · · 2024 · DOI 10.21203/rs.3.rs-5397300/v1
Verify or expand the search:
- PubMed search for NCT03361436
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Eribulin Mesylate
Trials testing the same drug.
- NCT06590558 — Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Er · Phase 1 · withdrawn
- NCT05041101 — Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer · Phase 1, PHASE2 · terminated
- NCT04579224 — Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothel · Phase 3 · active not recruiting
- NCT04345913 — Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer · Phase 1, PHASE2 · active not recruiting
- NCT05206656 — Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer · Phase 2 · completed
Other recruiting trials for Liposarcoma
Currently open trials in the same condition.
- NCT07169344 — Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma · Phase 2 · recruiting
- NCT07173972 — Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
- NCT06198296 — Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells · Phase 1 · recruiting
- NCT06843967 — A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma · Phase 1, PHASE2 · recruiting
Other OHSU Knight Cancer Institute trials
Trials by the same sponsor.
- NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
- NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
- NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
- NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03361436 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03361436.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing